CG Oncology (CG Oncology) Retained Earnings : $-146.87 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. CG Oncology's retained earnings for the quarter that ended in Mar. 2024 was $-146.87 Mil.

CG Oncology's quarterly retained earnings declined from Sep. 2023 ($-113.83 Mil) to Dec. 2023 ($-129.94 Mil) and declined from Dec. 2023 ($-129.94 Mil) to Mar. 2024 ($-146.87 Mil).

CG Oncology's annual retained earnings declined from Dec. 2021 ($-45.89 Mil) to Dec. 2022 ($-81.34 Mil) and declined from Dec. 2022 ($-81.34 Mil) to Dec. 2023 ($-129.94 Mil).

CG Oncology Retained Earnings Historical Data

The historical data trend for CG Oncology's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Retained Earnings Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Retained Earnings

-45.89

-81.34

-129.94

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial			-81.34	-	-113.83	-129.94	-146.87

CG Oncology Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

CG Oncology (NAS:CGON) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024